Grant: Canada Postdoctoral Research Award (CPRA) program
University of Calgary
$140,000.00
Plasma Biomarkers and Proteomic Signatures of Cerebral Amyloid Angiopathy: Disentangling CAA and Alzheimer's Disease Along the Amyloid Spectrum
FY 2025-26
Summary
Cerebral amyloid angiopathy (CAA) is a common disease caused by the buildup of a protein called amyloid-beta in the walls of the brain's blood vessels. It is closely linked to Alzheimer's disease (AD), another age-associated condition involving amyloid buildup. However, in AD, the protein forms plaques in brain tissue instead of blood vessels. CAA increases the risk of memory loss, dementia, and serious brain bleeds, yet it remains difficult to diagnose without advanced brain imaging and expert interpretation. This can lead to delayed diagnosis and increased risks of complications associated with certain treatments, especially in older adults.
Our research aims to find a simpler, non-invasive way to detect CAA using blood tests. Recent advances in Alzheimer's research have led to the development of blood biomarkers, which are measurable substances in the blood that reflect changes in the brain. However, we still don't know how well these tests work when CAA is present - or whether CAA has its own unique "fingerprint" of proteins in the blood.
Using data from a large Canadian aging study, we will compare blood samples from different groups of participants including older adults with cognitive impairment with and without CAA, and cognitively healthy individuals. We will also look at their brain images for specific lesions associated with CAA, and their relationship to measurable substances in the blood. Our goal is to see how well these blood tests can detect CAA, tell it apart from AD, and match up with visible brain changes on MRI.
If successful, this research could lead to earlier and more accurate diagnosis of CAA through a simple blood test. This would help doctors choose safer treatments for patients at risk of brain bleeds, improve care for people with dementia, and reduce harm from newer therapies for AD. Ultimately, it could improve brain health and quality of life for the more than 10,000 Canadians per year presenting with manifestations of CAA.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
536971
Name
Dallaire-Théroux Caroline
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Plasma Biomarkers and Proteomic Signatures of Cerebral Amyloid Angiopathy: Disentangling CAA and Alzheimer's Disease Along the Amyloid Spectrum
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Aging; Alzheimer'S Disease; Blood-Based Biomarkers; Cerebral Amyloid Angiopathy; Cognitive Impairment; Dementia; Diagnosis; Magnetic Resonance Imaging (Mri); Neuroimaging; Proteomics
Abstract
Cerebral amyloid angiopathy (CAA) is a common disease caused by the buildup of a protein called amyloid-beta in the walls of the brain's blood vessels. It is closely linked to Alzheimer's disease (AD), another age-associated condition involving amyloid buildup. However, in AD, the protein forms plaques in brain tissue instead of blood vessels. CAA increases the risk of memory loss, dementia, and serious brain bleeds, yet it remains difficult to diagnose without advanced brain imaging and expert interpretation. This can lead to delayed diagnosis and increased risks of complications associated with certain treatments, especially in older adults.
Our research aims to find a simpler, non-invasive way to detect CAA using blood tests. Recent advances in Alzheimer's research have led to the development of blood biomarkers, which are measurable substances in the blood that reflect changes in the brain. However, we still don't know how well these tests work when CAA is present - or whether CAA has its own unique "fingerprint" of proteins in the blood.
Using data from a large Canadian aging study, we will compare blood samples from different groups of participants including older adults with cognitive impairment with and without CAA, and cognitively healthy individuals. We will also look at their brain images for specific lesions associated with CAA, and their relationship to measurable substances in the blood. Our goal is to see how well these blood tests can detect CAA, tell it apart from AD, and match up with visible brain changes on MRI.
If successful, this research could lead to earlier and more accurate diagnosis of CAA through a simple blood test. This would help doctors choose safer treatments for patients at risk of brain bleeds, improve care for people with dementia, and reduce harm from newer therapies for AD. Ultimately, it could improve brain health and quality of life for the more than 10,000 Canadians per year presenting with manifestations of CAA.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dallaire-Théroux, Caroline
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~